Journal
AMERICAN JOURNAL OF SURGICAL PATHOLOGY
Volume 34, Issue 7, Pages 956-964Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PAS.0b013e3181e02f45
Keywords
triple negative; basal-like; immunohistochemistry; CK17; CD117; survival
Funding
- Department of Clinical Research, Singapore General Hospital [DCR/P26/2008]
- Singapore Cancer Syndicate [MS0004, MS4R]
Ask authors/readers for more resources
We earlier evaluated the relationship of 653 triple negative breast cancers (TNBC) with basal immunophenotypic expression by using antibodies to basal cytokeratins (CK5/6, CK14, CK17, 34 beta E12), p63, smooth muscle actin (SMA), epidermal growth factor receptor, and CD117, and found that a triple panel of CK14, 34bE12 and epidermal growth factor receptor determined 84% of our cases to be basal-like. Women with basal-like TNBC tended to be younger (P - 0.04), have histologically higher-grade tumors (P - 0.047), with positive nodal status (P = 0.047), than those whose tumors were nonbasal-like. Using univariate Cox regression analysis, tumor size (P = 0.003), histologic grade (P = 0.006), and nodal status (P = 0.017) were significant factors for disease-free survival (DFS) among TNBC, whereas age (P = 0.004), tumor size (P = 0.001), histologic grade (P < 0.001), nodal status (P = 0.011), lymphovascular invasion (P = 0.032), and pushing borders (P = 0.042) were important for overall survival (OS). On multivariate analysis, age was statistically significant for both DFS and OS (P = 0.033, 0.001 respectively), whereas histologic grade was important for OS (P < 0.001). Kaplan Meier curves showed CK17 positivity to impact adversely on DFS (P = 0.003) and OS (P = 0.014), whereas CD117 positive staining was accompanied by diminished OS (P = 0.036). SMA expression in TNBC however, revealed a trend for improved DFS (P = 0.05). Our findings indicate that basal-like TNBC are associated with adverse clinicopathologic parameters, and that individual biologic markers of CK17, CD117, and SMA have prognostic implications on survival. Possibilities exist for future targeted therapy for this challenging group of breast cancers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available